相似文献
1
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Neurology. 2013 Aug 27;81(9):850-2. doi: 10.1212/WNL.0b013e3182a2cc4a. Epub 2013 Jul 24.
2
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Neurology. 2014 May 20;82(20):1846-7. doi: 10.1212/01.wnl.0000450224.37865.80.
3
Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis.
Mult Scler Relat Disord. 2014 Nov;3(6):732-4. doi: 10.1016/j.msard.2014.08.001. Epub 2014 Aug 15.
4
Glatiramer acetate induced hepatotoxicity.
Curr Drug Saf. 2012 Apr;7(2):186-8. doi: 10.2174/157488612802715690.
5
Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
CNS Drugs. 2002;16(12):825-50. doi: 10.2165/00023210-200216120-00004.
6
Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
BioDrugs. 2003;17(3):207-10. doi: 10.2165/00063030-200317030-00007.
7
Glatiramer acetate for the treatment of multiple sclerosis.
Expert Opin Pharmacother. 2004 Apr;5(4):875-91. doi: 10.1517/14656566.5.4.875.
8
[Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
Zh Nevrol Psikhiatr Im S S Korsakova. 2003(Spec No 2):91-7.
9
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Mult Scler. 2000 Aug;6(4):255-66. doi: 10.1177/135245850000600407.
10
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
Cochrane Database Syst Rev. 2014 Jul 26(7):CD009333. doi: 10.1002/14651858.CD009333.pub2.
引用本文的文献
1
Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies.
Neurotherapeutics. 2025 Jul;22(4):e00631. doi: 10.1016/j.neurot.2025.e00631. Epub 2025 Jun 27.
2
Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database.
Sci Rep. 2025 Feb 8;15(1):4783. doi: 10.1038/s41598-025-89272-x.
3
Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?
Paediatr Drugs. 2025 Mar;27(2):161-179. doi: 10.1007/s40272-024-00675-1. Epub 2024 Dec 26.
4
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.
Curr J Neurol. 2023 Apr 4;22(2):115-136. doi: 10.18502/cjn.v22i2.13340.
5
Drug-induced liver injury by glatiramer acetate leading to liver transplant: A case report.
JGH Open. 2023 Jul 26;7(8):591-593. doi: 10.1002/jgh3.12938. eCollection 2023 Aug.
6
Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility.
Int J Mol Sci. 2023 Jan 3;24(1):852. doi: 10.3390/ijms24010852.
7
First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center.
Neurol Sci. 2023 Feb;44(2):693-701. doi: 10.1007/s10072-022-06431-y. Epub 2022 Oct 5.
8
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
CNS Drugs. 2022 Jan;36(1):45-59. doi: 10.1007/s40263-021-00887-w. Epub 2021 Dec 23.
9
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
CNS Drugs. 2021 Aug;35(8):861-880. doi: 10.1007/s40263-021-00842-9. Epub 2021 Jul 28.
10
Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments.
Paediatr Drugs. 2019 Jun;21(3):137-152. doi: 10.1007/s40272-019-00338-6.
本文引用的文献
1
Glatiramer acetate induced hepatotoxicity.
Curr Drug Saf. 2012 Apr;7(2):186-8. doi: 10.2174/157488612802715690.
2
Acute hepatitis induced by glatiramer acetate.
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.09.2008.0913. Epub 2009 Feb 27.
3
Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.
J Neurol. 2007 Jun;254(6):816-7. doi: 10.1007/s00415-006-0441-3. Epub 2007 Mar 12.
4
Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy.
Neurology. 2006 Jun 27;66(12):1954-5. doi: 10.1212/01.wnl.0000219764.27182.c7.
5
Drug-related hepatotoxicity.
N Engl J Med. 2006 Feb 16;354(7):731-9. doi: 10.1056/NEJMra052270.
6
Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report.
Eur J Neurol. 2001 Mar;8(2):199. doi: 10.1046/j.1468-1331.2001.00196.x.
7
Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
J Neurol. 2000 Sep;247(9):713. doi: 10.1007/s004150070118.
Zotero 插件